Literature DB >> 21470327

Rheumatic fever recurrence prevention: a nurse-led programme of 28-day penicillin in an area of high endemnicity.

Heather Spinetto1, Diana Lennon, Margaret Horsburgh.   

Abstract

AIMS: To evaluate safety and effectiveness of 28-day long-acting penicillin to prevent recurrences of acute rheumatic fever (ARF).
METHODS: Historical cohort study using the regional RF register for Auckland, New Zealand, in a 5-14-year-old population with ARF rates of ~40-80/100,000. Consented patients were referred to a population-based delivery programme of free benzathine penicillin every 28 days by community nurses with discharge after the longer of 10 years of treatment or aged 21 years. First-episode and recurrent ARF cases classified as definite (Jones criteria 1992) or probable (Jones criteria 1956) were the main outcome measures.
RESULTS: Of the 360 cases meeting the case definitions, 20 recurrences occurred in 19 people (median age 21 years). The age at first episode was 2-52 years (mode 11 years), median age 21.3 (8-40). ARF recurred 0-21 years after penicillin was discontinued. Seventy-two per cent of recurrent cases occurred within 5 years, and 12% between 5 years and 10 years. The 4-weekly long-acting penicillin failure rate (n= 1) was 0.07/100 patient years. The programme failure rate (Auckland residents) was 1.4/100 patient years (n= 20). Patient non-adherence accounted for 55% of recurrences. Two recurrences after discharge from prophylaxis as per the New Zealand guidelines occurred 3 years and 13 years later.
CONCLUSIONS: In this environment, 28-day long-acting penicillin prophylaxis for at least 10 years delivered by community nurses is safe and effective for patients with no or mild cardiac disease by auscultation at discharge off penicillin. Penicillin delivery every 21 days (as suggested by a recent Cochrane review) would add to costs and complexity.
© 2011 The Authors. Journal of Paediatrics and Child Health © 2011 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470327     DOI: 10.1111/j.1440-1754.2010.01942.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  13 in total

Review 1.  World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline.

Authors:  Bo Reményi; Nigel Wilson; Andrew Steer; Beatriz Ferreira; Joseph Kado; Krishna Kumar; John Lawrenson; Graeme Maguire; Eloi Marijon; Mariana Mirabel; Ana Olga Mocumbi; Cleonice Mota; John Paar; Anita Saxena; Janet Scheel; John Stirling; Satupaitea Viali; Vijayalakshmi I Balekundri; Gavin Wheaton; Liesl Zühlke; Jonathan Carapetis
Journal:  Nat Rev Cardiol       Date:  2012-02-28       Impact factor: 32.419

Review 2.  Acute rheumatic fever and rheumatic heart disease.

Authors:  Jonathan R Carapetis; Andrea Beaton; Madeleine W Cunningham; Luiza Guilherme; Ganesan Karthikeyan; Bongani M Mayosi; Craig Sable; Andrew Steer; Nigel Wilson; Rosemary Wyber; Liesl Zühlke
Journal:  Nat Rev Dis Primers       Date:  2016-01-14       Impact factor: 52.329

3.  Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever, Jamaica.

Authors:  Sheron Boswell Thompson; Cerese Hepburn Brown; Ann Marie Edwards; Jascinth L M Lindo
Journal:  Pathog Glob Health       Date:  2014-08-11       Impact factor: 2.894

Review 4.  Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease.

Authors:  Bo Remenyi; Jonathan Carapetis; Rosemary Wyber; Kathryn Taubert; Bongani M Mayosi
Journal:  Nat Rev Cardiol       Date:  2013-04-02       Impact factor: 32.419

5.  Failure of oral penicillin as secondary prophylaxis for rheumatic heart disease: a lesson from a low-prevalence rheumatic fever region.

Authors:  S M McGlacken-Byrne; H M Parry; P F Currie; N J Wilson
Journal:  BMJ Case Rep       Date:  2015-11-03

6.  Invasive group A streptococcal infection and vaccine implications, Auckland, New Zealand.

Authors:  Atheer Safar; Diana Lennon; Joanna Stewart; Adrian Trenholme; Dragana Drinkovic; Briar Peat; Susan Taylor; Kerry Read; Sally Roberts; Lesley Voss
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

7.  Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach.

Authors:  Anna P Ralph; Marea Fittock; Rosalie Schultz; Dale Thompson; Michelle Dowden; Tom Clemens; Matthew G Parnaby; Michele Clark; Malcolm I McDonald; Keith N Edwards; Jonathan R Carapetis; Ross S Bailie
Journal:  BMC Health Serv Res       Date:  2013-12-18       Impact factor: 2.655

8.  Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review.

Authors:  Priya M Kevat; Benjamin M Reeves; Alan R Ruben; Ronny Gunnarsson
Journal:  Curr Cardiol Rev       Date:  2017

9.  How Many Doses Make a Difference? An Analysis of Secondary Prevention of Rheumatic Fever and Rheumatic Heart Disease.

Authors:  Jessica Langloh de Dassel; Nick de Klerk; Jonathan Rhys Carapetis; Anna P Ralph
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

10.  Throat culture positivity rate and antibiotic susceptibility pattern of beta-hemolytic streptococci in children on secondary prophylaxis for rheumatic heart disease.

Authors:  Nigus Zegeye; Daniel Asrat; Yimtubezinash Woldeamanuel; Abebe Habte; Etsegenet Gedlu; Tone Tønjum; Abraham Aseffa
Journal:  BMC Infect Dis       Date:  2016-09-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.